PRMT5 and prostate cancer: This indicates that in prostate cancer bone metastasis, a BHLHE22-PRMT5-CSF2-mediated immunosuppressive pathway exists, which interacts with immune cells in the tumor microenvironment and jointly influences tumor progression and metastasis (46).